Business Context and Reporting Period
Company: Aethlon Medical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2026
Reporting Period: The filing reports on events occurring on June 4, 2026, specifically regarding an amendment to a prospectus supplement originally filed on December 23, 2025.
Key Financial Metrics
This filing is a current report regarding a securities offering and does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins.
| Metric | Value |
|---|---|
| Shares Eligible for Sale (New) | Aggregate offering price up to $542,716 |
| Shares Previously Sold (Under Prospectus) | Aggregate sales price of $1,849,457 |
| Total Common Stock Outstanding (as of June 1, 2026) | 2,344,886 shares |
| Public Float (Non-affiliate shares) | 2,337,629 shares |
Material Changes
The primary material change is the filing of Amendment No. 1 to the Prospectus Supplement on June 4, 2026. This amendment updates the amount of shares eligible for sale under the At Market Offering (ATM) Agreement with H.C. Wainwright & Co., LLC. Consequently, the Company may now offer and sell additional shares with an aggregate offering price of up to $542,716, in addition to the $1,849,457 previously sold under the original Prospectus Supplement.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms that all other terms of the offering and the ATM Agreement remain unchanged. The offering is registered under Form S-3 (File No. 333-292405), which became effective on January 2, 2026.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful prior to registration or qualification. The filing does not provide specific forward-looking guidance on business operations or financial projections beyond the mechanics of the stock offering.
Investor Verification Checklist
- Verify the current market price of AEMD to determine the approximate number of shares represented by the new $542,716 offering limit.
- Review the full Prospectus Supplement and the ATM Agreement for specific terms regarding sales commissions and lock-up provisions.
- Confirm the Company's cash position and burn rate to assess the necessity of this capital raise.
- Check for any subsequent filings regarding the actual execution of sales under the updated ATM Agreement.